News Releases

TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padelipor n vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced investment commitment of €13.5M from the European Innovation Council’s (EIC) Accelerator program, including a grant of €2.5M and a conditional equity investment … Continued

Promising response rate in patients with low-grade upper tract urothelial cancer (UTUC); complete response (CR) observed in 77% (10/13) of patients who completed the Induction Treatment Phase Padeliporfin VTP safe and efficacious, consistent with prior results and reinforcing initial clinical data from ENLIGHTED Preliminary efficacy data presented in a poster session at ASCO; additional interim … Continued

Encouraging response rate shown; CR in 67% (6/9) of patients who completed the Induction Treatment Phase Padeliporfin VTP generally well-tolerated, consistent with prior results and reinforcing differentiated organ-sparing profile Preliminary data presented in a podium session at AUA; additional interim results to be presented at ASCO TEL AVIV, Israel, May 06, 2024 (GLOBE NEWSWIRE) — … Continued

Preliminary results from Phase 3 ENLIGHTED study in low grade upper tract urothelial cancer (UTUC) to be presented at AUA and ASCO Trial design for Phase 1 study of Padeliporfin VTP in pancreatic ductal adenocarcinoma (PDAC) to be presented at ASCO TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology … Continued

TEL AVIV, Israel, Dec. 18, 2023 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat a range of solid tumors, today announced the appointment of Eyal Morag, M.D., as Chief Medical Officer (CMO). Dr. Morag brings extensive experience as a practicing clinical radiologist, specializing in … Continued

Phase 1 clinical trial expected to initiate in 1H 2024 IND clearance in third indication reflects broad platform potential for Padeliporfin VTP across a range of solid tumors   TEL AVIV, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat … Continued

ImPact Biotech to collaborate with Maastricht University researchers to progress a treatment to arrest the progressive condition Pathologic Myopia, a leading cause of irreversible sight impairment and blindness among adults   TEL AVIV, August 13, 2023 — ImPact Biotech, a leader in photodynamic therapy, recently announced an agreement with Maastricht University to collaborate in research focused … Continued

Padeliporfin VTP Phase 1 trial in Peripheral Non-Small Cell Lung Cancer to start by end Q4 2023   TEL AVIV, August 1, 2023 — ImPact Biotech, the IMmune Photo Activated Cancer Treatment (IMPACT) specialist announces the U.S. Food and Drug Administration cleared ImPact’s clinical investigation plan of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy for the treatment of patients with Peripheral Lung Cancer. … Continued

Designation confers advantages including marketing exclusivity and tax credits  Padeliporfin VTP Phase 1 trial in Pancreatic cancer to start by end Q4 2023   TEL AVIV, July 3, 2023 — ImPact Biotech, the IMmune Photo Activated Cancer Treatment (IMPACT) specialist announces the U.S. Food and Drug Administration granted Orphan Drug Designation (ODD) to Padeliporfin Vascular Targeted Photodynamic therapy (VTP) for the treatment of patients with … Continued

Pivotal Phase 3 trial recruiting 100 patients, and examining complete response of tumors as the primary endpoint. Consists of induction and maintenance phases, with follow up 12 months post treatment The activation of ENLIGHTED marks a significant milestone for Steba’s ambitious development program LUXEMBOURG, April 20, 2021 (GLOBE NEWSWIRE) —  Steba Biotech, the pioneering Immune Photo Activate Cancer Treatment (ImPACT) specialist, … Continued